Smidt Coronary heart Institute
One of many Smidt Coronary heart Institute’s main consultants in synthetic intelligence, David Ouyang, MD, has been named a deputy editor of NEJM AI–a newly established, peer-reviewed journal from the publishers of the extremely revered, New England Journal of Drugs.
David Ouyang, MD Notes
“Whereas there’s a great quantity of pleasure round synthetic intelligence, significantly because it pertains to healthcare, there stays a spot between analysis findings on restricted historic datasets and bringing unproven algorithms to the clinic and sufferers,” stated Ouyang, a college member within the Division of Cardiology within the Smidt Coronary heart Institute at Cedars-Sinai and within the Division of Synthetic Intelligence in Drugs.
Journal to Highlight
The not too long ago launched journal will highlight medical trials and practice-changing improvements, together with opinions, coverage views, and academic supplies designed particularly for training physicians and clinician leaders concerned with leveraging AI.
“There’s a eager curiosity in understanding and showcasing the outcomes of synthetic intelligence in medical apply and deployment, significantly with a watch on affected person affect,” stated Ouyang.
As a deputy editor, Ouyang is chargeable for the curation, screening and assessment of most of the submitted research and editorials about cardiology. He’s the one heart specialist among the many NEJM AI deputy editors.
At Cedars-Sinai, Ouyang’s analysis focus is on cardiac imaging in addition to software of synthetic intelligence and information science to healthcare. A statistician by coaching, Ouyang stated he has at all times been fascinated by understanding, visualizing, and deciphering information. As a heart specialist, he’s within the technology and evaluation of medical proof and information.
“The Smidt Coronary heart Institute and our broader tutorial enterprise have benefited drastically from David’s huge information and experience in giant language fashions, synthetic intelligence, imaging and cardiology. As an innovator within the area, we’re significantly honored to have David symbolize Cedars-Sinai, personifying our dedication to guide in AI medical purposes.”
Amongst his analysis achievements, Ouyang led the first-of-its-kind, blinded, randomized medical trial of AI in cardiology. The research discovered AI was superior in assessing cardiac perform in echocardiograms compared with assessments made by sonographers. The findings have been revealed in late 2023 within the peer-reviewed journal Nature.
Ouyang has revealed almost 100 tutorial analysis research in medical journals comparable to Journal of the American Faculty of Cardiology (JACC), European Coronary heart Journal, and Circulation.